KING OF PRUSSIA, PA, JULY 14, 2009—Tunnell Consulting, Inc. announced that its transition of the President and CEO’s role to Dr. Conrad J. Heilman, Jr., from Dr. Joseph S. Tempio was completed July 1.
Dr. Tempio will continue to serve as Chairman, a position he assumed in April 2006.
“Conrad possesses, in abundance, all of the qualities needed to continue to grow our firm’s reputation for providing innovative and sustainable solutions to our clients,” said Dr. Tempio, who has worked closely with Dr. Heilman to ensure a smooth transition. “He grew our Life Sciences business, and he brings to his new role a proven record of leadership and a history of accomplishments in life sciences research, development, manufacturing and regulatory affairs. He has been a driving force in our firm’s phenomenal growth, as evidenced by his involvement in securing contracts with the NIH and HHS. With his vision and industry expertise, particularly in the areas of vaccines and biotechnology, Conrad is ideally suited to lead us into the future.”
Dr. Heilman has served as Chief Operating Officer (COO) since the announcement of the planned succession in November 2008.
“Following in Joe’s footsteps is both an honor and a challenge,” Dr. Heilman said. “He has presided over a period during which the firm doubled revenues and grew our staff of life sciences experts by fifty percent. Most importantly, he has positioned the firm to anticipate and respond to the great challenges our clients face during this time of enormous transition in the life sciences industry. To meet those challenges, we will maintain our exclusive focus on the industry and develop new and differentiated services designed to help our clients improve their performance, improve quality and compliance and enhance profitability.”
Prior to becoming COO, Dr. Heilman served as Senior Vice President of the Life Sciences Strategic Operating Unit (SOU) with responsibility for the entire SOU, including the firm’s offices in King of Prussia, PA; California and Puerto Rico. Since joining the firm in 2000, he has spearheaded multi-million dollar projects for international firms and partnered with key clients to develop and implement initiatives to improve operational performance and regulatory compliance.
His experience prior to joining Tunnell includes roles at American Cyanamid, Lederle Laboratories; the DuPont Company, the DuPont Merck joint venture, Pro-Virus, Inc., a biotech; and ViroMed Laboratories, focused on biosafety. He earned his Ph.D. at The Johns Hopkins University, School of Public Health & Hygiene, and he has published numerous articles in peer-reviewed research journals and holds a number of scientific patents.
Dr. Tempio, prior to serving as President and CEO of Tunnell, headed the firm's largest practice, Pharmaceutical/Life Sciences Technical Services, and led the practice through its greatest growth period despite a difficult economy. In 2004, during his first year as CEO, he led Tunnell into the government life sciences market.
Before joining Tunnell, Dr. Tempio held significant positions in the pharmaceutical industry, including President of IBAH Pharmaceutical Services (now Omnicare Clinical Services), Director of Scientific Affairs for Lederle Consumer Healthcare (now a division of Wyeth), Director of Scientific Affairs at SmithKline Beecham Consumer Health (now GlaxoSmithKline), and key R&D, international and teaching positions. Dr. Tempio earned a B.S. degree in pharmacy from Duquesne University, and M.S. and Ph.D. degrees in pharmaceutical sciences from Rutgers University.
About Tunnell Consulting
Founded in 1962 and serving many of the world’s leading life sciences firms and government agencies, Tunnell Consulting, Inc. integrates strategic, technical and regulatory compliance skills to design and implement sustainable solutions that exactly meet client needs. With deep industry knowledge, extensive scientific and compliance credentials, and superior measurable results, we consistently boost the operating performance of each unique client we serve.